1.

table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

2.

table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

3.

table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

4.

table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

5.

table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

6.

table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

7.

table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

1.

Additional file 1 of Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians

1.

Additional file 2 of Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians

1.

Additional file 3 of Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians

1.

Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium

2.

Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium

3.

Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium

1.

Data_Sheet_1_Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice.docx

1.

Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice

1.

Population health management in Belgium: a call-to-action and case study

2.

Population health management in Belgium: a call-to-action and case study

3.

Population health management in Belgium: a call-to-action and case study

1.

Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders

1.

Public health impact and return on investment of Belgium’s pediatric immunization program